Yuh-Pyng Sher

Title: Yuh-Pyng Sher: Innovator in Lung Cancer Therapy Assessment

Introduction

Yuh-Pyng Sher is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer therapy, particularly in the rapid assessment of lung cancer treatment efficacy. His innovative approach has the potential to transform how lung cancer therapy is evaluated and monitored.

Latest Patents

Yuh-Pyng Sher holds a patent for a "Rapid efficacy assessment method for lung cancer therapy." This invention discloses a method that allows for the rapid assessment of lung cancer therapy efficacy within a few days, as opposed to the weeks required by conventional imaging methods. The method can also detect cancer relapse and improve the current TNM cancer staging method for more accurate prognosis. The rapid assessment is based on detecting circulating cancer cells in body fluid, achieving a high positive detection rate through qPCR amplification of multiple marker genes identified by an in silico search of DNA sequence databases. Additionally, the invention includes a scoring method to calculate cancer cell load based on qPCR results, correlating the amount of circulating cancer cells in lung cancer patients and predicting treatment outcomes. Yuh-Pyng Sher has 1 patent to his name.

Career Highlights

Yuh-Pyng Sher is affiliated with the National Health Research Institutes, where he continues to advance research in cancer therapy. His work has garnered attention for its innovative approach and potential impact on patient care.

Collaborations

Some of his notable coworkers include Konan Peck and Jin-Yuan Shih, who contribute to the collaborative efforts in research and development within the institution.

Conclusion

Yuh-Pyng Sher's contributions to lung cancer therapy assessment highlight the importance of innovation in medical research. His patented method represents a significant advancement in the field, offering hope for improved patient outcomes.